医学
阿法替尼
重症监护医学
药物开发
临床试验
药品
癌症
肿瘤科
药理学
内科学
埃罗替尼
表皮生长因子受体
作者
R. R. Hall,R. R. Hall,R. R. Hall,Matt Vassar,R. R. Hall,Alyson Haslam,Matt Vassar,R. R. Hall,R. R. Hall,R. R. Hall,R. R. Hall,R. R. Hall,Alyson Haslam
标识
DOI:10.1016/j.clinthera.2024.04.006
摘要
In 2013, afatinib was approved for non-small-cell lung cancer with subsequent indication expansion. We investigated published afatinib clinical trials to assess risk and benefit profiles for the drug in its approved indication of non-small-cell lung cancer as well as in off-label uses. Previous literature demonstrates excessive patient burden and limited benefit as afatinib has spread into more indications. A trial analysis is needed to establish efficacy and risk.
科研通智能强力驱动
Strongly Powered by AbleSci AI